A carregar...
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
BACKGROUND: Selected patients with advanced non-small cell lung cancer (NSCLC) benefit from immunotherapy, especially immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1) inhibitor. Peripheral blood biomarkers would be most convenient to predict treatment outcome and immune-re...
Na minha lista:
| Publicado no: | Cancer Immunol Immunother |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7413896/ https://ncbi.nlm.nih.gov/pubmed/32350592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02585-w |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|